ANDA 201899, held by Alkem Laboratories. Rasagiline Mesylate.
As of Nov 19, 2026, ANDA 201899 (Rasagiline Mesylate), held by Alkem Laboratories, was not approved, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 21, 2015 | Original application | Tentative approval | None posted |
| Rasagiline MesylateEQ 0.5MG BASE · tablet;oral | Rasagiline Mesylate | None (tentative approval) |
| Rasagiline MesylateEQ 1MG BASE · tablet;oral | Rasagiline Mesylate | None (tentative approval) |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters